The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Abstract
In contrast with the prevailing view that most tumors and metastases begin as avascular masses, evidence is presented here that a subset of tumors instead initially grows by coopting existing host vessels. This coopted host vasculature does not immediately undergo angiogenesis to support the tumor but instead regresses, leading to a secondarily avascular tumor and massive tumor cell loss. Ultimately, however, the remaining tumor is rescued by robust angiogenesis at the tumor margin. The expression patterns of the angiogenic antagonist angiopoietin-2 and of pro-angiogenic vascular endothelial growth factor (VEGF) suggest that these proteins may be critical regulators of this balance between vascular regression and growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,531
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
Self-citationTransplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning
Davis, S., Aldrich, T. H., Jones, P. F., Acheson, A., Compton, D. L., Jain, V., Ryan, T. E., Bruno, J., Radziejewski, C., Maisonpierre, P. C., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81812-7 · Cited by 1,989
Self-citationHolmgren, L., O'Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,878
Cited by
Angiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Self-citationTumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Pathogenesis and clinical features of psoriasis
Griffiths, C. E., & Barker, J. N. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61128-3 · Cited by 2,158
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Vascular niche for adult hippocampal neurogenesis
Palmer, T. D., Willhoite, A. R., & Gage, F. H. (2000) · The Journal of Comparative Neurology · doi:10.1002/1096-9861(20001002)425:4<479::aid-cne2>3.0.co;2-3 · Cited by 1,838
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Self-citationOpenings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Every step of the way: integrins in cancer progression and metastasis
Hamidi, H., & Ivaska, J. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0038-z · Cited by 1,493
Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
Augustin, H. G., Young Koh, G., Thurston, G., & Alitalo, K. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2639 · Cited by 1,465
Thun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2175 · Cited by 1,405
Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20069 · Cited by 1,372
De Palma, M., Venneri, M. A., Galli, R., Sergi, L. S., Politi, L. S., Sampaolesi, M., & Naldini, L. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.002 · Cited by 1,311
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., & Papahadjopoulos, D. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01426-1 · Cited by 1,263
Tumors as Organs: Complex Tissues that Interface with the Entire Organism
Egeblad, M., Nakasone, E. S., & Werb, Z. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.05.012 · Cited by 1,234
Tight junctions of the blood–brain barrier
Wolburg, H., & Lippoldt, A. (2002) · Vascular Pharmacology · doi:10.1016/s1537-1891(02)00200-8 · Cited by 1,183
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
Real-time imaging reveals the single steps of brain metastasis formation.
Kienast, Y., von Baumgarten, L., Fuhrmann, M., Klinkert, W. E. F., Goldbrunner, R., Herms, J., & Winkler, F. (2010) · Nature Medicine · doi:10.1038/nm.2072 · Cited by 1,138
Du, R., Lu, K. V., Petritsch, C., Liu, P., Ganss, R., Passegué, E., Song, H., VandenBerg, S., Johnson, R. S., Werb, Z., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.034 · Cited by 1,130
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
Dewhirst, M. W., Cao, Y., & Moeller, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2397 · Cited by 1,022
Molecular mechanisms of blood vessel growth
Conway, E. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00281-9 · Cited by 1,030
Gale, N. W., Thurston, G., Hackett, S. F., Renard, R., Wang, Q., McClain, J., Martin, C., Witte, C., Witte, M. H., Jackson, D., et al. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00217-4 · Cited by 1,018
Self-citationTumor angiogenesis: past, present and the near future
Kerbel, R. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.505 · Cited by 976
Brain metastases: epidemiology and pathophysiology
Gavrilovic, I. T., & Posner, J. B. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-8093-6 · Cited by 975
Aptamers: An Emerging Class of Therapeutics
Nimjee, S. M., Rusconi, C. P., & Sullenger, B. A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.062904.144915 · Cited by 937
Functional morphology of the blood–brain barrier in health and disease
Liebner, S., Dijkhuizen, R. M., Reiss, Y., Plate, K. H., Agalliu, D., & Constantin, G. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1815-1 · Cited by 872
Griffioen, A. W., & Molema, G. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01448-0 · Cited by 842
Mechanisms of normal and tumor-derived angiogenesis
Papetti, M., & Herman, I. M. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00389.2001 · Cited by 809
Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
Norden, A. D., Young, G. S., Setayesh, K., Muzikansky, A., Klufas, R., Ross, G. L., Ciampa, A. S., Ebbeling, L. G., Levy, B., Drappatz, J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000304121.57857.38 · Cited by 801
Cellular abnormalities of blood vessels as targets in cancer
Baluk, P., Hashizume, H., & McDonald, D. M. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.005 · Cited by 781
Michiels, C. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10333 · Cited by 773
Holash, J., Wiegand, S. J., & Yancopoulos, G. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203035 · Cited by 744
Self-citationFiedler, U., Scharpfenecker, M., Koidl, S., Hegen, A., Grunow, V., Schmidt, J. M., Kriz, W., Thurston, G., & Augustin, H. G. (2004) · Blood · doi:10.1182/blood-2003-10-3685 · Cited by 742
Endothelial Cell Heterogeneity
Aird, W. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006429 · Cited by 731
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis
Kaur, B., Khwaja, F. W., Severson, E. A., Matheny, S. L., Brat, D. J., & Van Meir, E. G. (2005) · Neuro-Oncology · doi:10.1215/s1152851704001115 · Cited by 725
“While Ang-1 is believed to stabilize and prevent leakiness of vessels, Ang-2 destabilizes the existing vasculature, causing vessel sprouting and new vessel growth in the presence of VEGF, but resulting in regression of vessels without the presence of VEGF (Holash et al., 1999).”
BackgroundKlaassen, I., Van Noorden, C. J. F., & Schlingemann, R. O. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.02.001 · Cited by 722
Specialization of tumour vasculature
Ruoslahti, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc724 · Cited by 722
Hypoxia: A key regulator of angiogenesis in cancer
Liao, D., & Johnson, R. S. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9066-y · Cited by 721
Role of nanotechnology in targeted drug delivery and imaging: a concise review
Koo, O. M., Rubinstein, I., & Onyuksel, H. (2005) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2005.06.004 · Cited by 718
Hattori, K., Dias, S., Heissig, B., Hackett, N. R., Lyden, D., Tateno, M., Hicklin, D. J., Zhu, Z., Witte, L., Crystal, R. G., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.9.1005 · Cited by 687
Vasculogenic Mimicry and Tumor Angiogenesis
Folberg, R., Hendrix, M. J. C., & Maniotis, A. J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64739-6 · Cited by 684
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Rafii, S., Lyden, D., Benezra, R., Hattori, K., & Heissig, B. (2002) · Nature Reviews Cancer · doi:10.1038/nrc925 · Cited by 679
Fagiani, E., & Christofori, G. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.08.018 · Cited by 676
Host cyclooxygenase-2 modulates carcinoma growth
Williams, C. S., Tsujii, M., Reese, J., Dey, S. K., & DuBois, R. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9621 · Cited by 673
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 672
Kim, I., Kim, H. G., So, J.-N., Kim, J. H., Kwak, H. J., & Koh, G. Y. (2000) · Circulation Research · doi:10.1161/01.res.86.1.24 · Cited by 649
MOLECULAR PATHOLOGY OF MALIGNANT GLIOMAS
Louis, D. N. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100043 · Cited by 648
Joyce, J. A., Baruch, A., Chehade, K., Meyer-Morse, N., Giraudo, E., Tsai, F.-Y., Greenbaum, D. C., Hager, J. H., Bogyo, M., & Hanahan, D. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00111-4 · Cited by 645
Mazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L. S., Gentner, B., Brown, J. L., Naldini, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.005 · Cited by 639
Therapeutic targeting of the angiopoietin–TIE pathway
Saharinen, P., Eklund, L., & Alitalo, K. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.278 · Cited by 620
Batchelor, T. T., Mulholland, P., Neyns, B., Nabors, L. B., Campone, M., Wick, A., Mason, W., Mikkelsen, T., Phuphanich, S., Ashby, L. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2464 · Cited by 614
Nimjee, S. M., White, R. R., Becker, R. C., & Sullenger, B. A. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104558 · Cited by 607
Gale, N. W., Dominguez, M. G., Noguera, I., Pan, L., Hughes, V., Valenzuela, D. M., Murphy, A. J., Adams, N. C., Lin, H. C., Holash, J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407290101 · Cited by 600
Self-citationVascular endothelial growth factor (VEGF) signaling in tumor progression
Roskoski, R. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.01.006 · Cited by 599
Tumour vascularization: sprouting angiogenesis and beyond
Hillen, F., & Griffioen, A. W. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9094-7 · Cited by 583
Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9670 · Cited by 582
“ANGPT2 neutralization might exacerbate vascular co-option by cancer cells (39), and there is also evidence that genetic Angpt2 deficiencymay aggravate the progression of colorectal liver metastasis in mice (40).”
BackgroundVEGF as a Therapeutic Target in Cancer
Ferrara, N. (2005) · Oncology · doi:10.1159/000088479 · Cited by 578
Vascular Endothelial Growth Factor as a Target for Anticancer Therapy
Ferrara, N. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_1-2 · Cited by 574
Rong, Y., Durden, D. L., Van Meir, E. G., & Brat, D. J. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-200606000-00001 · Cited by 567
Nonlinear modelling of cancer: bridging the gap between cells and tumours
Lowengrub, J. S., Frieboes, H. B., Jin, F., Chuang, Y.-L., Li, X., Macklin, P., Wise, S. M., & Cristini, V (2010) · Nonlinearity · doi:10.1088/0951-7715/23/1/r01 · Cited by 553
Disruption of astrocyte–vascular coupling and the blood–brain barrier by invading glioma cells
Watkins, S., Robel, S., Kimbrough, I. F., Robert, S. M., Ellis-Davies, G., & Sontheimer, H. (2014) · Nature Communications · doi:10.1038/ncomms5196 · Cited by 550
De Palma, M., Venneri, M. A., Roca, C., & Naldini, L. (2003) · Nature Medicine · doi:10.1038/nm871 · Cited by 549
The Role of Prolactin in Mammary Carcinoma
Clevenger, C. V., Furth, P. A., Hankinson, S. E., & Schuler, L. A. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0036 · Cited by 545
Batchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520
Reynolds, L. P., & Redmer, D. A. (2001) · Biology of Reproduction · doi:10.1095/biolreprod64.4.1033 · Cited by 516
Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer
Gimple, R. C., Bhargava, S., Dixit, D., & Rich, J. N. (2019) · Genes & Development · doi:10.1101/gad.324301.119 · Cited by 514
Rubenstein, J. L., Kim, J., Ozawa, T., Zhang, M., Westphal, M., Deen, D. F., & Shuman, M. A. (2000) · Neoplasia · doi:10.1038/sj.neo.7900102 · Cited by 509
Polymeric nanomedicine for cancer therapy
Park, J. H., Lee, S., Kim, J.-H., Park, K., Kim, K., & Kwon, I. C. (2008) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.09.003 · Cited by 506
A Role for Hematopoietic Stem Cells in Promoting Angiogenesis
Takakura, N., Watanabe, T., Suenobu, S., Yamada, Y., Noda, T., Ito, Y., Satake, M., & Suda, T. (2000) · Cell · doi:10.1016/s0092-8674(00)00025-8 · Cited by 506
Pericytes and vascular stability
VONTELL, D., ARMULIK, A., & BETSHOLTZ, C. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.10.019 · Cited by 502
Role of hypoxia in the hallmarks of human cancer
Ruan, K., Song, G., & Ouyang, G. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22214 · Cited by 489
Brat, D. J., Castellano-Sanchez, A. A., Hunter, S. B., Pecot, M., Cohen, C., Hammond, E. H., Devi, S. N., Kaur, B., & Van Meir, E. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2073 · Cited by 485
VEGF and angiopoietin signaling in tumor angiogenesis and metastasis
Saharinen, P., Eklund, L., Pulkki, K., Bono, P., & Alitalo, K. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.015 · Cited by 478
Mechanisms of Glioma-Associated Neovascularization
Hardee, M. E., & Zagzag, D. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.06.030 · Cited by 475
Self-citationAngiogenesis Inhibitors: Current Strategies and Future Prospects
Cook, K. M., & Figg, W. D. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20075 · Cited by 474
Saharinen, P., Eklund, L., Miettinen, J., Wirkkala, R., Anisimov, A., Winderlich, M., Nottebaum, A., Vestweber, D., Deutsch, U., Koh, G. Y., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1715 · Cited by 471
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2
Oliner, J., Min, H., Leal, J., Yu, D., Rao, S., You, E., Tang, X., Kim, H., Meyer, S., Han, S. J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.030 · Cited by 471
Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities
Hida, K., Hida, Y., Amin, D. N., Flint, A. F., Panigrahy, D., Morton, C. C., & Klagsbrun, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1567 · Cited by 470
Diffuse Glioma Heterogeneity and Its Therapeutic Implications
Nicholson, J. G., & Fine, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1474 · Cited by 460
Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Niu, G., & Chen, X. (2010) · Current Drug Targets · doi:10.2174/138945010791591395 · Cited by 451
Molecular Mediators of Angiogenesis
Ucuzian, A. A., Gassman, A. A., East, A. T., & Greisler, H. P. (2010) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e3181c7ed82 · Cited by 446
Kuczynski, E. A., Vermeulen, P. B., Pezzella, F., Kerbel, R. S., & Reynolds, A. R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0181-9 · Cited by 446
Günther, H. S., Schmidt, N. O., Phillips, H. S., Kemming, D., Kharbanda, S., Soriano, R., Modrusan, Z., Meissner, H., Westphal, M., & Lamszus, K. (2008) · Oncogene · doi:10.1038/sj.onc.1210949 · Cited by 443
Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis
Fearon, U., Canavan, M., Biniecka, M., & Veale, D. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.69 · Cited by 439
The seed and soil hypothesis: vascularisation and brain metastases
Fidler, I. J., Yano, S., Zhang, R.-D., Fujimaki, T., & Bucana, C. D. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00622-2 · Cited by 432
Circulating endothelial precursors: mystery, reality, and promise
Rafii, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8774 · Cited by 432
Geiger, T. R., & Peeper, D. S. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.07.006 · Cited by 431
Vasculogenesis and Angiogenesis
Patan, S. (2004) · Cancer Treatment and Research · doi:10.1007/978-1-4419-8871-3_1 · Cited by 430
Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis
Karkkainen, M. J., & Petrova, T. V. (2000) · Oncogene · doi:10.1038/sj.onc.1203855 · Cited by 427
The organ microenvironment and cancer metastasis
Fidler, I. J. (2002) · Differentiation · doi:10.1046/j.1432-0436.2002.700904.x · Cited by 426
Heterogeneity of the Tumor Vasculature
Nagy, J., Chang, S.-H., Shih, S.-C., Dvorak, A., & Dvorak, H. (2010) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0030-1253454 · Cited by 422
Tie receptors: new modulators of angiogenic and lymphangiogenic responses
Jones, N., Iljin, K., Dumont, D. J., & Alitalo, K. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35067005 · Cited by 418
Folkman, J. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00133-5 · Cited by 415
The hypoxic response of tumors is dependent on their microenvironment
Blouw, B., Song, H., Tihan, T., Bosze, J., Ferrara, N., Gerber, H.-P., Johnson, R. S., & Bergers, G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00194-6 · Cited by 408
The role of the Angiopoietins in vascular morphogenesis
Thomas, M., & Augustin, H. G. (2009) · Angiogenesis · doi:10.1007/s10456-009-9147-3 · Cited by 405
Bunone, G., Vigneri, P., Mariani, L., Butó, S., Collini, P., Pilotti, S., Pierotti, M. A., & Bongarzone, I. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65515-0 · Cited by 404
Wang, B., Xiao, Y., Ding, B.-B., Zhang, N., Yuan, X.-B., Gui, L., Qian, K.-X., Duan, S., Chen, Z., Rao, Y., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00164-8 · Cited by 398
Metadata
- Authors
- Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J.
- Venue
- Science
- Published
- 1999-06-18
- Volume
- 284
- Issue
- 5422
- Pages
- 1994-1998
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2012255417
- Cited by
- 2,195
- References
- 37
- FWCI
- 35.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.